CXCL8 secreted by primary ESCC cells can inhibit the function of natural killer cells (NK cells) through the STAT3 pathway, leading to tumor immune escape; therefore, immune-boosting therapeutic strategies targeting CXCL8 may benefit ESCC patients [38]. This evidence concerns the gene STAT3 and neoplasm.